Trouble ahead?

How to maintain a stable, innovative health sector in Europe

8 November 2017, Stanhope Hotel, Brussels

Programme

17:45 Reception

18:15 Welcome, Richard L. Hudson, Editor-in-chief and Vice-Chair of

the Board, Science|Business
Q&A with Clare Moody, Member, European Parliament

18:35 Innovation Markets: How do we maintain a single market for

healthcare innovation?

• Line Matthiessen, Director for Health, DG Research &

Innovation, European Commission
• Pascale Augé, CEO, Inserm Transfert
• Anna Sandström, Science Relations Director, AstraZeneca
• Annemarie Haverhals, Leader, Value Based Healthcare
Program, Santeon

19:15 Dinner Debate: What are the minimum requirements for a vibrant
pan-European health sector – for researchers, start-ups, pharma,
doctors, administrators and patients?

21:30 Carriages
 Featured Guests

Pascale Augé
CEO, Inserm Transfert

Pascale Augé is CEO of Inserm Transfert. Augé previously led Institut Pasteur’s
technology transfer office. She has more than 15 years’ experience in the
fields of innovation in life science and health technology, research transfer
and entrepreneurship, and the biotechnology start-up industry. She headed
business development at Neurotech, Entomed and AB Science, and ran Ernst &
Young activities in France. She also chaired the evaluation committee reviewing
“high-market-potential products, technologies or services” at France’s Agence
Nationale de la Recherche from 2008 to 2011.

Annemarie Haverhals
Programme Leader for Value Based Health Care, Santeon

Annemarie Haverhals is Value Based Healthcare director at the Dutch hospital

group Santeon. Haverhals is responsible for the development and implementation
of a VBHC work method, in which outcomes that matter to patients, costs
incurred and throughput times are measured and compared between the
seven hospitals for the main disease areas. Prior to leading this programme,
Haverhals was responsible for strategy and quality department at OLVG hospital
in Amsterdam for 5 years. Haverhals is an economist (Erasmus University) with
extensive strategic consulting experience at McKinsey & Company and her own
consulting firm.

Line Matthiessen
Acting Director for Health, DG Research and Innovation, European Commission

Line Matthiessen is acting director of the Directorate for Health, in the Directorate-
General for Research and Innovation at the European Commission. In this role, her
responsibilities include providing overall strategic orientation and management
of the directorate. Matthiessen is also the head of unit responsible for fighting
infectious diseases and advancing public health in the same directorate. The unit
promotes research and innovation in the area of global health with emphasis on
HIV/AIDS, malaria and tuberculosis, emerging epidemics, neglected infectious
diseases and antimicrobial drug resistance.
 Featured Guests

Clare Moody
Member, European Parliament

Clare Moody was elected as a Labour Member of the European Parliament for
the South West of England and Gibraltar in 2014. Moody is currently the vice-
chair of the Subcommittee on Security and Defence, and sits on the Committee
on Foreign Affairs, the Committee on Industry, Research and Energy, and the
Committee on Women´s Rights and Gender Equality. Prior to being elected as
an MEP, Moody spent her working life as a trade unionist representing people in
a wide variety of industries, including as a regional officer for Unite the Union in
the South West.

Anna Sandström
Science Relations Director, AstraZeneca

Anna Sandström is science relations director at AstraZeneca. Sandström

develops new R&D collaborations with academia, companies and third party
groups, and contributes to life science polices in the EU and Sweden. Sandström
is a board member of the Royal Institute of Technology, the MaxIV synchrotron
X-ray source, the drug discovery and development platform at the Science for
Life Laboratory, and heads the R&D committee at the trade body SwedenBIO.
She has previously worked for Swedish government agencies such as Vinnova
and the Ministry of Enterprise and Innovation as well as the Royal Academy of
Engineering Sciences.
 Guests

• Pascale Augé, CEO, Inserm Transfert

• Jaana Backman, Director, LEAR, University of Eastern Finland
• Anne Borge, Professor; Member, Horizon 2020 advisory group on SC1, University of Oslo
• David Boyd, Director, European Government Affairs, AstraZeneca
• Jan Brosens, Deputy Head, Biomedical Sciences, Warwick Medical School
• Andrea Chiarello, Manager, EU Government Affairs, Pfizer
• Vincent Clay, Senior Manager, EU Government Affairs, Pfizer
• Gian Marco Currado, Counsellor, Social and Environment, Permanent Representation of the United
Kingdom to the EU
• Kris Dejonckheere, Secretary General, UNICA
• Monica Dietl, Senior Advisor, Science|Business
• Francesco Florindi, Engagement Officer, Biobanking and Biomolecular Research Infrastructure
• Hayley Furlong, Research Programme Officer, Trinity Biomedical Sciences Institute
• Miguel Gonzalez-Sancho, Head of Unit, eHealth, Well-Being and Ageing, DG Communications
Networks, Content and Technology, European Commission
• Douglas Gregory, Executive Director, European Union Government Affairs, Amgen
• Ari Grönroos, Executive Director, Funding Operations, Tekes - The Finnish Funding Agency
• Malcolm Harbour, Senior Advisor, CabinetDN / European Policy Centre
• Annemarie Haverhals, Programme Leader for Value Based Health Care, Santeon
• Mathias Havgar, Representative in Brussels, Innovation Norway
• Lukas Heinisch, Junior Consultant, Interel / Frontiers
• Minna Hendolin, Director, Health and Wellbeing, Tekes - The Finnish Funding Agency
• Matti Hiltunen, Head of Brussels Office, Tekes - The Finnish Funding Agency
• Graeme Holland, Healthcare Policy Europe; Chair, COCIR Public Affairs Group, GE Healthcare
• Richard L. Hudson, Editor-in-chief and Vice-Chair of the Board, Science|Business
• Frédéric Jaisser, Head, Integrative Physiology and Pathophysiology, Cordeliers Research Center
• Line Matthiessen, Acting Director for Health, DG Research and Innovation, European Commission
• Janne Martikainen, Professor, Health Economics, University of Eastern Finland
• Clare Moody, Member, European Parliament
• Liberty Oberlander, Head, Membership Development, Association of Commonwealth Universities
• Jan Palmowski, Secretary General, The Guild
• Terje Peetso, Head of Sector, eHealth and Ageing Policy, DG Communications Networks, Content and
Technology, European Commission
• Nina Renshaw, Secretary General, European Public Health Alliance
• Milena Richter, Head of EU office, Public Affairs Europe, Sanofi
• Anna Sandström, Science Relations Director, AstraZeneca
• Luciano Saso, Vice-Rector, European University Network, Sapienza University of Rome
• Julia Schmalenberg, Senior Policy Advisor, Fraunhofer
• Ortwin Schulte, Health Attaché; Head of Unit, Health Policy, Permanent Representation of the Federal
Republic of Germany to the European Union
• Jennifer Shum, EU Government Affairs Director, AstraZeneca
• Charlotte Thorley, Senior Manager, Science|Business
• Effy Vayena, Professor, Health Policy, Health Ethics and Policy Lab, Institute for Epidemiology,
Biostatistics and Prevention, ETH Zürich